<DOC>
	<DOC>NCT02690701</DOC>
	<brief_summary>This study will evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.</brief_summary>
	<brief_title>Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Males and females at least 18 years of age with moderate to severe plaque psoriasis Forms of psoriasis other than chronic plaque psoriasis Previous exposure to IL17A or IL17 receptor targeting agents. Other active or ongoing disease that may interfere with evaluation of psoriasis or places the patient at unacceptable risk Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>secukinumab</keyword>
	<keyword>AIN457</keyword>
	<keyword>biologic</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>